Understanding Pharma: The Professional's Guide To How Pharmaceutical And Biotech Companies Really Work Hardcover – March 12, 2018

It very succinctly explains the Pharma and manages to do it in a reasonable amount of time. If you are in Pharma or would like to understand about Pharma this is a great book to start with.

I'm a PhD interested in the pharma space and after a ton of reading the ins and outs, I found this to be most accessible, thorough text for a high level overview of the pharma space. The price is totally justified given the very high quality content of text and printing. Essential reading in 2023 !

Excellent book with so much useful information for those navigating a career in medical, regulatory, and/or commercial affairs within a pharma or biotech firm. Some typos and errors are present, but this doesn’t take away from the total value of the book. Highly recommend.

Having working as an employee of multiple Pharma companies, and as a director of consulting for Pharma and Biotech companies, I believe this book provides a great overview of the industry. Believe it should be priced a little lower though.

This is a very comprehensive book. Highly recommended for anyone who wants to learn all the nuances of the pharmaceutical company.

Very comprehensive information on the industry

Exactly as described. Good Quality.

I purchased this book as a pharmacist on internship at a biotech company. I like how the book is structured. It’s easily digestible and full of general data about the U.S. healthcare sector, but there are just too many big mistakes for a book presenting summary data from external publications. I’ve noticed 4 (2 major) so far and am only on page 56. It’s a waste of time when the reader walks away not knowing what to believe.Attaching a couple of helpful examples in case the publisher actually reads this.Attachment 1 is an expanded pie chart that’s mislabeled. The specialists come out of the PCP slice and the PCP subspecialties come out of the specialists slice.Attachment 2 is a misleading chart. The emerging market slice is over twice as large as the EU, but the difference is only 4 billion. The “rest of the world” slice is also twice as large but presents $100 billion, half the EU.